CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 1,363 enrolled
Drug / intervention
Dexamethasone +6 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03367572
NCT03367572Phase 3Completed

Netupitant/Palonosetron Hydrochloride and Dexamethasone With or Without Prochlorperazine or Olanzapine in Improving Chemotherapy-Induced Nausea and Vomiting in Patients With Breast Cancer

University of Rochester NCORP Research Base·interventional·Posted Dec 8, 2017·Updated Sep 25, 2025

In Brief

A Phase 3 clinical trial evaluating Dexamethasone, Laboratory Biomarker Analysis, and 5 other interventions for Breast Carcinoma. Completed, enrolled 1,363 participants across 18 sites.

Detailed Summary

This randomized phase III trial studies how well netupitant/palonosetron hydrochloride and dexamethasone with prochlorperazine or olanzapine work compared to netupitant/palonosetron hydrochloride and dexamethasone in improving chemotherapy-induced nausea and vomiting in patients with breast cancer. Antiemetic drugs, such as prochlorperazine and olanzapine, may help lessen nausea and vomiting in patients with breast cancer treated with chemotherapy.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States

Timeline

Phase 3CompletedFinished
201820192020202120222023202420252026
First PostedDec 8, 2017
Enrollment StartApr 19, 2018
Primary CompletionApr 13, 2024
TodayJul 2, 2026
Enrollment to primary: 6.0 yearsPosted 8.6 years ago

Interventions

Dexamethasonedrug

Given PO

Laboratory Biomarker Analysisother

Correlative studies

Netupitant/Palonosetron Hydrochloridedrug

Given PO

Olanzapinedrug

Given PO

Placeboother

Given PO

Prochlorperazinedrug

Given PO

Quality-of-Life Assessmentother

Ancillary studies